# EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders

> **NCT02321475** · — · COMPLETED · sponsor: **Ipsen** · enrollment: 54 (actual)

## Conditions studied

- Cognitive Disorders

## Interventions

- **DRUG:** EGb761®

## Key facts

- **NCT ID:** NCT02321475
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2020-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02321475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02321475, "EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02321475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*